Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors.

Zhu, Xuguang; Holmsen, Erik; Park, Sunmi; Willingham, Mark C; Qi, Jun; Cheng, Sheue-Yann

Zhu, Xuguang; Holmsen, Erik; Park, Sunmi; Willingham, Mark C; Qi, Jun; Cheng, Sheue-Yann.

Afiliación

Zhu X; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Holmsen E; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Park S; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Willingham MC; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Qi J; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Cheng SY; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Oncotarget ; 9(83): 35408-35421, 2018 Oct 23.

Article en En | MEDLINE | ID: mdl-30459933

Palabras clave

JQ1; anaplastic thyroid cancer; bromodomain and extraterminal protein inhibitor; trametinib; tumorigenesis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google